Financial Performance Summary - In 2025, the company achieved operating revenue of 288.27 million RMB, a decrease of 4.99% compared to the previous year [3] - The net profit attributable to the parent company was a loss of 19.09 million RMB, which represents a reduction in losses by 57.33% year-on-year [3] - Total assets at the end of the reporting period were 1.54 billion RMB, a decrease of 0.71% from the beginning of the year [3] - The equity attributable to the parent company was 1.39 billion RMB, down 1.47% from the beginning of the year [3] Operational Factors - The company continued to expand into new areas of biopharmaceutical technology, enhancing product market competitiveness and optimizing marketing strategies [4] - Despite increased sales volume due to entry into large aquaculture supply chains, revenue and gross margin slightly declined due to competitive pricing pressures in the animal health industry [4] - Delays in customer payments led to an increase in accounts receivable and higher credit impairment losses [4] - The company adjusted its operational strategy, focusing on customer needs and achieving progress in the development of multi-valent vaccines [4] Investment and Future Plans - The company invested in a stake in an innovative drug company, Yangzhou Shizhi Source Biotechnology Co., Ltd., which is conducting clinical research on innovative drugs [5] - The company plans to gain controlling interest in Shizhi Source through its wholly-owned subsidiary, Shanghai Bentiancheng Biotechnology Co., Ltd., integrating it into the consolidated financial statements [5] - Future plans include leveraging biotechnological advantages to accelerate the development and launch of innovative drugs, including treatments for HIV and allergy monoclonal antibodies [6] Credit Impairment Provision - The company plans to recognize a credit impairment provision of 12.76 million RMB for the year 2025 [11] - This provision is based on expected credit losses from accounts receivable, notes receivable, and other receivables [11] - The impact of this provision on the company's total profit for 2025 is estimated to be 12.76 million RMB, excluding tax effects [12]

Core Viewpoint - The company expects a net profit of approximately -20 million yuan for the year 2025, which represents a reduction in losses of about 24.74 million yuan compared to the previous year, indicating a year-on-year loss reduction of approximately 55% [1] Group 1: Financial Performance - The company's net profit attributable to the parent company and the net profit after deducting non-recurring gains and losses are both expected to show losses for 2025 [1] - The overall sales revenue and gross margin have slightly decreased compared to the same period last year due to intense competition in the animal health industry and a decline in vaccine product prices [1] - The increase in accounts receivable due to delayed customer payments has led to a rise in credit impairment losses [1] - The depreciation of fixed assets has increased following the commissioning of a new vaccine workshop [1] Group 2: Strategic Developments - The company is actively expanding into new areas of biopharmaceutical technology and optimizing its marketing layout, resulting in increased product sales volume [1] - The company has made significant progress in the research and development of multi-valent vaccines, with new products such as the swine fever genetic engineering subunit vaccine and the swine streptococcus disease/infectious pleuropneumonia bivalent vaccine being launched [1] - The total period expenses have significantly decreased compared to the previous year, contributing to a reduction in net profit losses by approximately 55% [1] Group 3: Investment and Future Plans - The company has invested in a stake in the innovative drug company Yangzhou Shizhi Yuan Biotechnology Co., Ltd., which is conducting clinical research on innovative drugs [2] - The company plans to acquire a controlling stake in Shizhi Yuan to synergize its human and animal health businesses, leveraging its advanced biotechnology and production advantages in the human innovative drug sector [2] - The company aims to expedite the research and development and market launch of several innovative drugs, including monoclonal antibodies for AIDS [2]

Core Viewpoint - The company expects a net profit of approximately -20 million yuan for the year 2025, which represents a reduction in losses by about 24.74 million yuan compared to the previous year, indicating a year-on-year loss reduction of approximately 55% [1] Group 1: Financial Performance - The company's net profit attributable to the parent company and the net profit after deducting non-recurring gains and losses both showed losses during the reporting period [1] - The overall sales revenue and gross margin slightly decreased compared to the same period last year due to intense competition in the animal health industry and a decline in vaccine product prices [1] - The increase in accounts receivable due to delayed customer payments led to a rise in credit impairment losses [1] Group 2: Strategic Developments - The company is actively expanding into new areas of biopharmaceutical technology and optimizing its marketing layout, resulting in increased product sales volume [1] - The company has made significant progress in the research and development of multi-valent vaccines, with new products such as the swine fever genetic engineering subunit vaccine and the swine streptococcus disease/infectious pleuropneumonia bivalent vaccine being launched [1] - The total period expenses have significantly decreased compared to the previous year, contributing to a reduction in net profit losses by approximately 55% [1] Group 3: Investment and Future Plans - The company has invested in a stake in the innovative drug company Yangzhou Shizhi Yuan Biotechnology Co., Ltd., which is conducting clinical research on innovative drugs [2] - The company plans to acquire a controlling stake in Shizhi Yuan to synergize its human medicine and animal health businesses, leveraging its advanced biotechnological and production capabilities for the development of innovative drugs [2] - The company aims to expedite the research and market launch of several innovative drugs, including monoclonal antibodies for AIDS [2]

Core Viewpoint - The company Shunlian Bio has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its genetically engineered subunit vaccine for swine fever, along with the issuance of the veterinary drug product approval number [1] Group 1 - The approval signifies a significant milestone for the company's product development in the veterinary vaccine sector [1] - The vaccine is expected to enhance the company's market position in the animal health industry [1] - This development may lead to increased revenue opportunities for the company in the future [1]

Core Viewpoint - The city of Hohhot is striving to become the leading hub for veterinary vaccine research and production in China, driven by significant technological breakthroughs and supportive policies in the biopharmaceutical industry [1][3][5] Group 1: Technological Breakthroughs - Jin Yu Bao Ling Biopharmaceutical Co., Ltd. launched the "Jin Niu Zhi" vaccine, marking a major technological advancement in China's biopharmaceutical sector [1] - The company has also established an intelligent manufacturing line capable of producing 8 million doses of pet vaccines annually, which has passed GMP static acceptance [1] - The establishment of the Inner Mongolia Animal Vaccine Technology Innovation Center aims to enhance vaccine research and development, focusing on major animal diseases [2][3] Group 2: Industry Growth and Collaboration - Hohhot has seen its biopharmaceutical industry output grow from 13.11 billion yuan in 2020 to 20.25 billion yuan in 2024, with 117 research institutions and 602 drug registration approvals [4] - The city has actively collaborated with prestigious institutions like the Chinese Academy of Sciences and Tsinghua University to accelerate vaccine development [4] - The introduction of high-value product projects by local companies aims to enhance the quality and innovation of animal serum and vaccine production [2][4] Group 3: Policy Support and Investment - Hohhot has implemented various policies to support the high-quality development of the biopharmaceutical industry, including financial incentives totaling 14 million yuan for innovation platforms and vaccine projects [3] - The city is positioning itself as a national leader in veterinary vaccine production, with significant investments in research and development infrastructure [5] - The establishment of the National Swine Technology Innovation Center in Inner Mongolia signifies the region's commitment to becoming a key player in the animal vaccine industry [4]